The effects of DPP-4 inhibitors (DPP-4i) on postoperative outcomes and tumor biology in diabetic patients with colorectal cancer (CRC) were investigated in a retrospective study involving 260 patients with T2D who underwent curative resection for CRC. This evidence concerns the gene DPP4 and colorectal carcinoma.